Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis.
Many physicians are reluctant to treat elderly glioblastoma (GBM) patients as aggressively as younger patients, which is not evidence based due to the absence of validated data from primary studies. We conducted a meta-analysis to provide valid evidence for the use of the aggressive combination of r...
Main Authors: | An-an Yin, Lu-hua Zhang, Jin-xiang Cheng, Yu Dong, Bo-lin Liu, Ning Han, Xiang Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3782499?pdf=render |
Similar Items
-
Radiotherapy plus temozolomide in elderly patients with glioblastoma: a “real-life” report
by: J. Biau, et al.
Published: (2017-12-01) -
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
by: Makoto Ohno, et al.
Published: (2019-11-01) -
Brain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis.
by: Qian Zhao, et al.
Published: (2016-01-01) -
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review
by: Ricardo J. Komotar M.D., et al.
Published: (2008-01-01) -
Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results.
by: Takahiro Oike, et al.
Published: (2013-01-01)